



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the Role of Nanoparticle Albumin Bound (Nab) Paclitaxel
(Abraxane®) in Metastatic Breast Cancer (MBC)**

Approved Use:

Nab-Paclitaxel: As a **single agent treatment option** in a q 3 week schedule (as a first, second, or third line therapy) for patients with metastatic breast cancer (MBC) who have an ECOG performance status of 0 to 2 and choose to receive systemic chemotherapy. Nab-paclitaxel in the adjuvant setting is currently **not** recommended.

- This policy recommendation represents a **new guideline document** and a restriction of nab-paclitaxel as a treatment option for patients with MBC.